U.S. flag

An official website of the United States government

NM_000527.5(LDLR):c.681C>A (p.Asp227Glu) AND Cardiovascular phenotype

Germline classification:
Pathogenic (1 submission)
Last evaluated:
May 26, 2021
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV002365580.2

Allele description [Variation Report for NM_000527.5(LDLR):c.681C>A (p.Asp227Glu)]

NM_000527.5(LDLR):c.681C>A (p.Asp227Glu)

Gene:
LDLR:low density lipoprotein receptor [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
19p13.2
Genomic location:
Preferred name:
NM_000527.5(LDLR):c.681C>A (p.Asp227Glu)
HGVS:
  • NC_000019.10:g.11105587C>A
  • NG_009060.1:g.21207C>A
  • NM_000527.5:c.681C>AMANE SELECT
  • NM_001195798.2:c.681C>A
  • NM_001195799.2:c.558C>A
  • NM_001195800.2:c.314-1805C>A
  • NM_001195803.2:c.314-978C>A
  • NP_000518.1:p.Asp227Glu
  • NP_000518.1:p.Asp227Glu
  • NP_001182727.1:p.Asp227Glu
  • NP_001182728.1:p.Asp186Glu
  • LRG_274t1:c.681C>A
  • LRG_274:g.21207C>A
  • LRG_274p1:p.Asp227Glu
  • NC_000019.9:g.11216263C>A
  • NM_000527.4:c.681C>A
Protein change:
D186E
Links:
dbSNP: rs121908028
NCBI 1000 Genomes Browser:
rs121908028
Molecular consequence:
  • NM_001195800.2:c.314-1805C>A - intron variant - [Sequence Ontology: SO:0001627]
  • NM_001195803.2:c.314-978C>A - intron variant - [Sequence Ontology: SO:0001627]
  • NM_000527.5:c.681C>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001195798.2:c.681C>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001195799.2:c.558C>A - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
Cardiovascular phenotype
Identifiers:
MedGen: CN230736

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV002664174Ambry Genetics
criteria provided, single submitter

(Ambry Variant Classification Scheme 2023)
Pathogenic
(May 26, 2021)
germlineclinical testing

PubMed (8)
[See all records that cite these PMIDs]

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Identification and characterization of novel low-density lipoprotein receptor mutations of familial hypercholesterolaemia patients in Taiwan.

Charng MJ, Chiou KR, Chang HM, Cheng HM, Ye ZX, Lin SJ.

Eur J Clin Invest. 2006 Dec;36(12):866-74.

PubMed [citation]
PMID:
17087781

The molecular basis of familial hypercholesterolemia in the Czech Republic: spectrum of LDLR mutations and genotype-phenotype correlations.

Tichý L, Freiberger T, Zapletalová P, Soška V, Ravčuková B, Fajkusová L.

Atherosclerosis. 2012 Aug;223(2):401-8. doi: 10.1016/j.atherosclerosis.2012.05.014. Epub 2012 May 23.

PubMed [citation]
PMID:
22698793
See all PubMed Citations (8)

Details of each submission

From Ambry Genetics, SCV002664174.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (8)

Description

The p.D227E pathogenic mutation (also known as c.681C>A), located in coding exon 4 of the LDLR gene, results from a C to A substitution at nucleotide position 681. The aspartic acid at codon 227 is replaced by glutamic acid, an amino acid with highly similar properties. This alteration, which is also known as p.D206E, has been reported in familial hypercholesterolemia (FH) cohorts in both the heterozygous and homozygous states (Charng MJ et al. Eur J Clin Invest, 2006 Dec;36:866-74; Hooper AJ et al. Atherosclerosis, 2012 Oct;224:430-4; Reiman A et al. Ann Clin Biochem, 2016 Nov;53:654-662; Hori M et al. Atherosclerosis, 2019 10;289:101-108). In addition, a different alteration located at the same position, resulting in the same protein change, c.681C>G (p.D227E), is a founder mutation that accounts for the majority of FH in the Afrikaner population (Leitersdorf et al. J Clin Invest.1989;84(3):954-61; King et al. N Z Med J. 2010;123(1319):79-82) and had also been reported in affected individuals of multiple ethnicities (Gudnason et al. Arterioscler. Thromb. 1993;13(1):56-63; Leren et al. Semin Vasc Med. 2004;4(1):75-85; Bertolini et al Atherosclerosis 2013;227(2):342-348; Sharifi et al. Metab. Clin. Exp. 2016;65(3):48-53). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Apr 13, 2025